Apatinib plus standard therapy for advanced breast cancer
Part of Cancer clinical trials.
This trial tests adding apatinib to a doctor-chosen standard treatment for advanced, hormone receptor-positive breast cancer that is HER2-negative. The goal is to see if this combination slows cancer growth in patients who have progressed after endocrine therapy and CDK4/6 inhibitors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced breast cancer that is HER2-negative and hormone receptor-positive
- You have already tried endocrine therapy and a CDK4/6 inhibitor, and the cancer continued to grow
- You have received no more than 3 different chemotherapy treatments for advanced cancer
- You are 18 or older, able to care for yourself (ECOG 0 or 1), and have a life expectancy of at least 3 months
- You have a tumor that can be measured on scans, such as CT or MRI
- Your organs (blood, liver, kidneys) are working well enough, and you have no major bleeding risks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, apatinib and a CDK4/6 inhibitor, as the first treatment for a specific type of advanced breast cancer that is HR+ and HER2-. It's designed for people with the 'SNF4' subtype, which is identified by a special analysis of your tumor sample.
This Phase 2 study tests whether apatinib combined with a CDK4/6 inhibitor and hormone therapy can better control advanced hormone receptor–positive, HER2-negative breast cancer. It may help shrink tumors or slow their growth, especially in cases that can’t be fully treated with surgery or radiation.
This trial tests a combination of two oral targeted drugs (fluzoparib and apatinib) against standard chemotherapy for women with advanced, HRD-positive, HER2-negative breast cancer. It may be an option if you have already received some treatments but not too many.
This trial studies how well apatinib plus albumin-bound paclitaxel works for advanced triple-negative breast cancer that has come back or spread. It may help shrink tumors and control the disease by targeting cancer growth in more than one way.
This trial tests a combination of two oral drugs—capecitabine (a chemotherapy pill) and pyrotinib (a targeted therapy)—for people with HER2-positive breast cancer that has spread. It is for those who have already had a recent type of targeted therapy called an ADC and are looking for a new treatment option that does not require a hospital visit.
This trial tests a combination of three drugs—capecitabine (a chemotherapy pill), camrelizumab (an immunotherapy), and apatinib (a targeted therapy)—for people with advanced pancreatic cancer whose previous treatment stopped working or who cannot tolerate standard chemotherapy.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.